Showing results (61-70 of 91) with videos related to
Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinasesMichael C Heinrich, Heikki Joensuu, George D Demetri, et al.British Journal of Cancer|May 20, 2017
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastasesSagun Parakh, John J Park, Shehara Mendis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.Lancet (London, England)|October 19, 2006
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialGeorge D Demetri, Allan T van Oosterom, Christopher R Garrett, et al.JAMA Oncology|July 3, 2025
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical TrialBo Gao, Matteo S Carlino, Michael Michael, et al.NPJ Digital Medicine|September 29, 2024
Blending space and time to talk about cancer in extended realityTamsin J Robb, Yinan Liu, Braden Woodhouse, et al.Cancer Cell|December 16, 2010
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3KJessie Villanueva, Adina Vultur, John T Lee, et al.European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studySara Valpione, Matteo S Carlino, Johanna Mangana, et al.Journal for Immunotherapy of Cancer|October 9, 2021
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)Peter Kar Han Lau, Breon Feran, Lorey Smith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2026
Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trialAdnan Nagrial, Matteo S Carlino, Ashray Gunjur, et al.Pageof 10